147 related articles for article (PubMed ID: 20607752)
21. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
22. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
23. Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes.
Toprani A; Fonseca V
Diabetes Obes Metab; 2011 Mar; 13(3):276-80. PubMed ID: 21205120
[TBL] [Abstract][Full Text] [Related]
24. Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database.
Rascati KL; Richards KM; Lopez D; Cheng LI; Wilson JP
Clin Ther; 2011 Dec; 33(12):2016-20. PubMed ID: 22101160
[TBL] [Abstract][Full Text] [Related]
25. Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes.
Asche CV; McAdam-Marx C; Shane-McWhorter L; Sheng X; Plauschinat CA
Diabetes Obes Metab; 2008 Aug; 10(8):638-45. PubMed ID: 17645555
[TBL] [Abstract][Full Text] [Related]
26. A cohort study of thiazolidinediones and fractures in older adults with diabetes.
Solomon DH; Cadarette SM; Choudhry NK; Canning C; Levin R; Stürmer T
J Clin Endocrinol Metab; 2009 Aug; 94(8):2792-8. PubMed ID: 19470635
[TBL] [Abstract][Full Text] [Related]
27. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary.
Jermendy G; ; Erdesz D; Nagy L; Yin D; Phatak H; Karve S; Engel S; Balkrishnan R
Health Qual Life Outcomes; 2008 Oct; 6():88. PubMed ID: 18976457
[TBL] [Abstract][Full Text] [Related]
29. Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
Lee SJ; Ha KH; Lee JH; Lee H; Kim DJ; Kim HC
PLoS One; 2019; 14(2):e0211959. PubMed ID: 30742667
[TBL] [Abstract][Full Text] [Related]
30. Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study.
Lin HC; Hsu YT; Kachingwe BH; Hsu CY; Uang YS; Wang LH
J Clin Pharm Ther; 2014 Aug; 39(4):354-60. PubMed ID: 24661226
[TBL] [Abstract][Full Text] [Related]
31. Effect of dipeptidyl peptidase IV inhibitors, thiazolidinedione, and sulfonylurea on osteoporosis in patients with type 2 diabetes: population-based cohort study.
Yang BR; Cha SH; Lee KE; Kim JW; Lee J; Shin KH
Osteoporos Int; 2021 Sep; 32(9):1705-1712. PubMed ID: 33594487
[TBL] [Abstract][Full Text] [Related]
32. Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes.
Prentice JC; Conlin PR; Gellad WF; Edelman D; Lee TA; Pizer SD
Value Health; 2014 Dec; 17(8):854-62. PubMed ID: 25498781
[TBL] [Abstract][Full Text] [Related]
33. Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan.
Ou HT; Chen YT; Liu YM; Wu JS
Diabetes Res Clin Pract; 2016 Jun; 116():14-25. PubMed ID: 27321311
[TBL] [Abstract][Full Text] [Related]
34. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Tzoulaki I; Molokhia M; Curcin V; Little MP; Millett CJ; Ng A; Hughes RI; Khunti K; Wilkins MR; Majeed A; Elliott P
BMJ; 2009 Dec; 339():b4731. PubMed ID: 19959591
[TBL] [Abstract][Full Text] [Related]
35. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
36. Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study.
Lee YC; Chang CH; Dong YH; Lin JW; Wu LC; Hwang JS; Chuang LM
Int J Cardiol; 2017 Feb; 228():1007-1014. PubMed ID: 27923207
[TBL] [Abstract][Full Text] [Related]
37. Effects of thiazolidinediones on cardiovascular events in patients with type 2 diabetes mellitus after drug-eluting stent implantation: a retrospective cohort study using the national health insurance database in Taiwan.
Yeh HT; Hsieh CF; Tsai YW; Huang WF
Clin Ther; 2012 Apr; 34(4):885-93. PubMed ID: 22440193
[TBL] [Abstract][Full Text] [Related]
38. Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults.
Wang T; Hong JL; Gower EW; Pate V; Garg S; Buse JB; Stürmer T
Diabetes Care; 2018 Sep; 41(9):1998-2009. PubMed ID: 30012674
[TBL] [Abstract][Full Text] [Related]
39. Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias.
Bowker SL; Lin M; Eurich DT; Johnson JA
Can J Diabetes; 2017 Apr; 41(2):204-210. PubMed ID: 27908558
[TBL] [Abstract][Full Text] [Related]
40. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
